ClinicalTrials.gg
RecruitingNCT05570812SOOTHEUpdated Sep 12, 2025

Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV

A Phase 2 interventional study of Placebo and Pregnenolone in Major Depressive Disorder, Anxiety Depression and HIV, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 88 studies in Depressive Disorder, Major by Massachusetts General Hospital — 9 open to participants now, 12 under way, none of them phase 3. Depressive Disorder, Major · Massachusetts General Hospital.

Planned enrollment
12th of 77
120 · median 40
Started
2023
with 2 others
Phase 2
14 of 88
3 open now
Primary completion
2027-06
later than 7 of 11 live
Registered
81st of 88
by date

Among the 88 studies in Depressive Disorder, Major by Massachusetts General Hospital, this one is the 12th largest by planned enrollment of the 77 interventional ones that give a count, is one of 3 that started in 2023, is one of 14 in phase 2, reaches primary completion later than 7 of the 11 other live ones, and was the 81st registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

9 of the 88 studies in Depressive Disorder, Major by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Depressive Disorder, Major by Massachusetts General Hospital, or all of them as a file.
02

Study summary

This study will determine the effects of pregnenolone on brain function, inflammation and depressive symptoms in people with HIV who have depression. Participants in this study will receive a pill of either pregnenolone or placebo, and can stay on their current antidepression medications. Brain imaging and behavioral assessments will be performed during the study.

Read the detailed description

Pregnenolone is a neuroactive steroid that exhibits actions highly relevant to treating depression in people with HIV. The investigators' recent human data suggest that neuroactive steroids are decreased in people with HIV and depression. In addition, multiple groups have reported reductions in neuroactive steroids in people without HIV who have depression. A total of 120 people living with HIV on antiretroviral therapy with depression will be randomized to either pregnenolone or placebo (2 groups/90 participants receiving pregnenolone and 30 participants receiving placebo). Drug dosage will begin at 50 mg daily and incrementally increase to 500 mg daily within the first 4 weeks, with a stable 500 mg/day regimen for the final 4 weeks. Behavioral testing and blood draw will be performed at baseline, 2 weeks, 4 weeks, and 8 weeks, while magnetic resonance spectroscopy (MRS), and task-based functional magnetic resonance imaging (MRI) will be conducted at 2 weeks and 8 weeks.

The investigators hypothesize that pregnenolone will be well-tolerated in people with HIV and depression, and that this intervention may improve brain activity and reduce inflammation.

03

Conditions studied

  • Major Depressive Disorder
  • Anxiety Depression
  • HIV

Keywords

  • HIV
  • Depression
  • Neuroactive Steroid
  • Pregnenolone
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-85 years
  • -1 viral load \<200 copies/mL on antiretroviral therapy (ART) at screening visit
  • Center for Epidemiological Studies - Depression (CES-D) score ≥ 20

Exclusion criteria

Exclusion Criteria:

  • to magnetic resonance imaging (MRI) or poor-quality baseline MRI preventing image analyses as determined by radiologist assessment
  • Recent severe infections including opportunistic infections, active bacterial, mycobacterial, fungal, or certain viral infections
  • Vulnerable populations (e.g., pregnant/nursing, severe cognitive or intellectual impairment, incarcerated)
  • Use of cobicistat or ritonavir
  • High risk for suicide (active suicidal ideation (SI) with plan/intent as assessed by using the Columbia Suicide Severity Rating (C-SSRS) or > 2 attempts in lifetime or any in the past 6 months) or expresses homicidal ideation necessitating clinical intervention or representing an imminent concern
  • Any severe (life-threatening or unstable) medical condition as determined by clinician assessment
  • Blood pressure, with the lowest reading taken after three repeat readings during screening visit, ≥ 160 mmHg systolic OR ≥ 95 mmHg diastolic or other life-threatening vital signs as determined by clinician assessment
  • abnormalities in physical examination or that would interfere with study participation
  • Decompensated cirrhosis, active liver inflammation ( (ALT)/aspartate aminotransferase (AST) ≥ 5 times the ) or unsuppressed viral or C infection
  • Severe renal disease (estimated ≤ 30 mL/min/1.73m2)
  • Seizure disorder requiring antiepileptic treatment
  • History of allergic reaction or side effects with prior pregnenolone use
  • Currently using testosterone enanthate, testosterone cypionate, or estrogen containing preparations that significantly increase systemic estrogen levels, including but not limited to oral and transdermal forms of estrogen. All other forms of exogenous sex hormones will be evaluated at the discretion of the PI and/or clinical delegates.
  • Currently using systemic agents, including corticosteroids, chemotherapy, or specific immunomodulating agents, such as monoclonal antibodies and TNF-inhibitors
  • Excessive alcohol or other substances use that would interfere with classification of major depression disorder, study procedures and/or follow-up
  • Current diagnosis of bipolar disorder
  • Diagnosis of a psychotic disorder (current or lifetime)
  • Diagnosis of schizophrenia (current or lifetime)
  • \<70% adherence to study drug prior to randomization
  • Inability to swallow pills/capsules
  • Not able to complete neuropsychological testing in English
  • Concurrent participation in another interventional trial, except for lifestyle and device studies (For vaccination studies, individuals in the observation period are not exclusionary. Other interventions will be evaluated at the discretion of the PI and/or clinical delegates.)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Placebo

    Participants will be on the following dosage schedule: 50 mg daily for 2 weeks, THEN 100 mg daily for 1 week, THEN 250 mg daily for 1 week, THEN 500 mg daily for 4 weeks

    Drug: Placebo

  • Experimental
    Pregnenolone

    Participants will be on the following dosage schedule: 50 mg daily for 2 weeks, THEN 100 mg daily for 1 week, THEN 250 mg daily for 1 week, THEN 500 mg daily for 4 weeks

    Drug: Pregnenolone

Interventions

  • DrugPlacebo

    (4-week ramp, 4-week steady dosing)

  • (4-week ramp, 4-week steady dosing)

    Also known as: Neuroactive steroid

06

What researchers measure

Primary outcomes

  1. Gamma-aminobutyric acid (GABA) Concentration

    Comparison between Pregnenolone and Placebo Groups of Left Insular Cortex GABA Concentration, Adjusted for Baseline.

    Time frame: Day 14, Day 56

Secondary outcomes

  1. Center for Epidemiological Studies-Depression (CES-D; scores range from 0 (no symptoms) to 60 (maximum severity of depressive symptoms))

    Comparison of Percentage of Pregnenolone and Placebo Groups Showing Clinical Improvement of Depression at Study End. The revised CES-D is administered, and the total score is calculated by adding the responses to the 20 questions.

    Time frame: Day 0, Day 14, Day 56

  2. CD14+CD16+ Monocytes

    Comparison of the Percentage of CD14+CD16+ Monocytes Over Time Adjusted for Baseline Between Pregnenolone and Placebo Groups

    Time frame: Day 0, Day 14, Day 28, Day 56

  3. GABA Concentration in Responders

    Comparison of Baseline Left Insular Cortex GABA and Pregnenolone Between Participants in Pregnenolone Group with Clinical Improvement Compared to Clinical Non-Improvers in Pregnenolone Group

    Time frame: Day 0, Day 14, Day 56

  4. Adverse Events

    Comparison of the Incidence and Severity of Adverse Events Between Pregnenolone and Placebo Groups

    Time frame: Day 14, Day 56

  5. Dose Modifications

    Comparison of Dose Modifications Required Between Pregnenolone and Placebo Groups

    Time frame: Day 14, Day 56

07

Study locations

1 of 1 sites recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
    • Shibani Mukerji, MD, PhD · Principal investigator
08

References and documents

Publications

  • Mukerji SS, Misra V, Lorenz DR, Chettimada S, Keller K, Letendre S, Ellis RJ, Morgello S, Parker RA, Gabuzda D. Low Neuroactive Steroids Identifies a Biological Subtype of Depression in Adults with Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy. J Infect Dis. 2021 May 20;223(9):1601-1611. doi: 10.1093/infdis/jiaa104. PubMed 32157292 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Jun 2027, 51 months after the start.

Of 99 non-industry phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 57. This study's planned 51 months is above that.

Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2022
First posted
Oct 7, 2022
StartActual
Mar 3, 2023
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jan 31, 2028
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05570812
Collaborators
National Institute of Mental Health (NIMH), Institute for Medical Research, Inc.
Responsible party
Shibani Mukerji (Assistant Professor of Neurology, Massachusetts General Hospital) — Principal investigator
First posted
Oct 7, 2022
Start date
Mar 3, 2023
Primary completion
Jun 30, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Sep 12, 2025

Study contacts

Hemi Park, MPH
Contact
MGHSOOTHE@PARTNERS.ORG
857-282-3788
Shibani S. Mukerji, MD, PhD
Contact
SMUKERJI@MGB.ORG
857-282-9950
Shibani S. Mukerji, MD, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregnenolone

Start the discussion